title: Granulomatosis and polyangiitis: the rituximab option.
authors: Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
authors: Ari
authors: A
authors: Polachek
authors: Dan
authors: D
authors: Caspi
authors: Ori
authors: O
authors: Elkayam
mesh_terms: D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D003937:Diagnosis, Differential; D005260:Female; D005921:Glomerulonephritis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D005938:Glucocorticoids / Q000008:administration & dosage; D014890:Granulomatosis with Polyangiitis / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D007668:Kidney / Q000473:pathology / Q000503:physiopathology; D008168:Lung / Q000000981:diagnostic imaging / Q000503:physiopathology; D008875:Middle Aged; D009916:Orbital Diseases / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D011859:Radiography; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab